Exhibit 99.1 Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' dif erentiated array of highly ef ective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., August 19, 2025 – Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a leading medical device and technology ...

Financial Data and Key Metrics Changes - In Q2 2025, revenue decreased by approximately 6% to $3.8 million compared to $4.1 million in 2024, reflecting additional expenses related to the transition and integration of the Sleep Center of Nevada (SCN) [8][10] - Operating loss widened to $4.9 million in Q2 and $8.8 million for 2025, primarily due to higher expenses and lower revenues during the strategic transition [11][12] - Cash and cash equivalents stood at $4.4 million with total liabilities of $21.5 million as of June 30, 2025 [12] Business Line Data and Key Metrics Changes - VIP enrollment revenue declined by $1 million in Q2, while sleep testing service revenue saw an uplift of $500,000 attributable to SCN [9][10] - Oral appliance sales decreased by 5% in Q2, with 4,116 units sold for $1.9 million, reflecting a shift towards higher volume guide sales [10][11] Market Data and Key Metrics Changes - The integration of SCN has led to increased patient demand, with the company currently servicing significantly less than 40% of potential new patients being tested each month at SCN [18][19] - The company has identified a significant number of legacy SCN patients dissatisfied with CPAP units, indicating a strong market opportunity for VIVOS's treatment alternatives [18] Company Strategy and Development Direction - The company is focusing on a new sales, marketing, and distribution model centered around sleep center provider alliances and acquisitions, with the SCN acquisition being a key milestone [6][12] - VIVOS plans to expand its operations by deploying additional Sleep Optimization (SO) teams to meet growing patient demand, with potential for up to eight teams at SCN based on current demand [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the integration of SCN and the initial patient demand exceeding expectations, leading to plans for facility expansion and additional staff recruitment [14][18] - The company anticipates becoming cash flow positive by the fourth quarter of 2025 as it ramps up the deployment of SO teams [49] Other Important Information - The company has secured significant debt and equity financing, providing $11.5 million in net cash from financing activities [11][12] - VIVOS is actively pursuing additional acquisition and affiliation opportunities across the country, with ongoing negotiations with several potential candidates [22][39] Q&A Session Summary Question: How should revenue in Q3 and Q4 be viewed relative to Q2? - Management indicated that revenue will track the deployment of SO teams, with expectations for growth as the new model replaces the old one [26][27] Question: Will the strength in sleep testing services continue? - Management noted that the increase in testing revenue is a direct reflection of SCN's operations and expects continued growth as more testing centers are brought online [28][29] Question: What is the expected operating expense moving forward? - Management acknowledged that there were one-time costs associated with the SCN acquisition, but some ongoing costs will remain [31][32] Question: How is the recruitment of SO teams progressing? - Management reported robust demand for positions and efficient training processes for new teams [35][36] Question: What is the financial strategy regarding debt? - Management is focused on reducing the cost of capital and is exploring opportunities for refinancing as the business model matures [44][45] Question: When does management expect to reach cash breakeven? - Management is targeting cash flow positivity by the fourth quarter of 2025 as they expand operations [49]

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Large accelerated filer ☐ Accelerated filer ☐ Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Chart ...

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its second quarter 2025 financial results and will conduct a conference call to discuss these results and recent developments in the company [1][2][3] Company Overview - Vivos Therapeutics, Inc. specializes in developing and commercializing treatments for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [4] - The company’s devices are FDA-cleared for all severity levels of OSA in adults and moderate to severe OSA in children aged 6 to 17 [4] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [4] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [5] - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [5] Strategic Initiatives - Founded in 2016, Vivos aims to empower healthcare providers to better address the needs of OSA patients through innovative technology and collaborations [6] - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [7]

Core Insights - Vivos Therapeutics has received approval from the Centers for Medicare & Medicaid Services (CMS) for its VidaSleep™ oral appliance, which is designed to treat mild to moderate obstructive sleep apnea (OSA) and snoring in adults [1][4][5] - The approval allows Vivos to significantly expand its market presence, as it now has two Medicare-covered oral appliances, enhancing its competitive position in the sleep therapy market [5][6] Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on innovative treatments for OSA and snoring, with its products cleared by the FDA for various severity levels of OSA [10][12] - The company aims to address the structural root causes of OSA through its proprietary oral appliances, which are non-invasive and non-pharmaceutical [13] Market Opportunity - With over 80% of OSA cases in the U.S. undiagnosed and an estimated 80 million Americans affected, Vivos is positioned to capture a significant share of the underpenetrated sleep therapy market [4][11] - The dual-PDAC approval of VidaSleep™ and mmRNA® appliances allows Vivos to serve a broader range of patients, from Medicare beneficiaries to those covered by commercial payers, tapping into the estimated $36 billion sleep therapy market [6][8] Clinical and Commercial Advantages - The VidaSleep™ device is designed to be a standalone therapy or an adjunct to CPAP, providing flexibility for both providers and patients [7][8] - The streamlined design and efficient manufacturing process of VidaSleep™ enable Vivos to offer high-impact therapy at a cost-effective price, increasing adoption across Medicare and commercial insurance networks [8] Health Implications - OSA is linked to severe comorbidities such as heart disease, stroke, and dementia, yet remains largely underdiagnosed [9][11] - Vivos' oral appliances have shown significant improvements in airway patency and symptom resolution, as evidenced by peer-reviewed studies [9]

Core Insights - Vivos Therapeutics has announced a significant study published in the European Journal of Pediatrics, demonstrating the safety and efficacy of its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in children [1][2] - The study indicates that 79% of participants showed improvement in OSA symptoms, with 61.7% improving by 50% or more, and 17% experiencing complete resolution of their OSA [3] - The findings support Vivos' FDA 510(k) clearance for the DNA device, reinforcing its position as a non-surgical alternative to traditional adenotonsillectomy surgery [2][7] Company Overview - Vivos Therapeutics, Inc. is focused on developing non-invasive treatments for OSA, with its DNA device being a key product cleared for use in children aged 6 to 17 [9][12] - The company aims to address the significant number of undiagnosed OSA cases among children, estimated at 10 million in the U.S., with many linked to various health issues [5][10] - Vivos is actively pursuing collaborations and acquisitions to expand access to its treatments, including the recent acquisition of the Sleep Center of Nevada [9][11] Industry Context - The current standard treatment for pediatric OSA is adenotonsillectomy, with over 500,000 surgeries performed annually in the U.S., but with a high relapse rate of 68% within three years [6][7] - The study highlights the need for safer, evidence-based alternatives to invasive procedures, aligning with recent reports warning against overtreatment in pediatric healthcare [7][8] - Vivos' approach offers a non-invasive solution that promotes natural jaw development, potentially reducing the need for costly and traumatic surgeries [7][8]

Core Insights - Vivos Therapeutics has completed the acquisition of The Sleep Center of Nevada (SCN), enhancing its diagnostic revenue and expanding its treatment options for obstructive sleep apnea (OSA) patients in the Las Vegas area [1][2] - The acquisition marks a strategic pivot in Vivos' business model, shifting focus from dental providers to collaborations with medical sleep practices, allowing for immediate revenue capture from OSA diagnostics and consultations [3][6] - Vivos has secured over $11 million in financing, including a senior secured loan and an equity private placement, to support the integration of SCN and future growth initiatives [9][11] Acquisition Details - The SCN transaction is Vivos' first major acquisition of a sleep testing center, expected to generate higher-margin revenue from both diagnostics and sales of Vivos' OSA treatment devices [2][5] - SCN serves approximately 3,000 new patients monthly and has generated annual net revenues in the high seven-figure range, making it the largest sleep testing center in Nevada [5][6] - Vivos will manage SCN's operations and capture diagnostic and consulting revenues, with plans to expand treatment offerings across additional SCN locations over the next 12 to 18 months [7][11] Financial Aspects - The acquisition involved a cash payment of $6 million and $1.5 million in Vivos common stock, with potential future stock payments based on financial milestones [8] - Vivos financed the acquisition through an $8.225 million senior secured loan, which includes a $675,000 original issuance discount, and an additional $3.755 million equity investment from New Seneca Partners [9][10] - The financing will provide essential cash resources for Vivos to integrate SCN and pursue further growth opportunities [11] Strategic Outlook - Vivos is actively seeking additional collaborations or acquisitions to further expand its business in 2025 and beyond [4] - The company anticipates significant benefits from the SCN acquisition, including reduced cash burn and a move towards cash flow positivity as patient volumes increase [12]

Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.45 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $1.63 per share a year ago [1] - The company posted revenues of $3.02 million for the quarter, missing the Zacks Consensus Estimate by 18.49%, and down from $3.42 million in the same quarter last year [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates [2] Stock Performance - Vivos Therapeutics shares have declined approximately 29.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The current Zacks Rank for Vivos Therapeutics is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $4.2 million, and for the current fiscal year, it is -$1.54 on revenues of $16.6 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $3 million, down from $3.4 million in Q1 2024, primarily due to lower service revenue from VIP enrollments [20] - Product sales increased by approximately $100,000, while sponsorship, conference, and training revenue rose by $200,000 [20] - Gross profit decreased to $1.5 million in Q1 2025 from $1.9 million in Q1 2024, with gross margin dropping to 50% from 57% [21][22] - Operating loss for Q1 2025 was approximately $3.9 million, slightly higher than the $3.8 million loss in Q1 2024 [24] Business Line Data and Key Metrics Changes - Service revenues declined as the company eliminated its VIP enrollment sales team, while product sales, particularly in pediatric guide appliances, grew significantly, with total arches shipped increasing by 87% [8][20] - The billing intelligence service and myofunctional therapy service revenue remained unchanged at $200,000 for both Q1 2024 and Q1 2025 [20] Market Data and Key Metrics Changes - The company is expecting to close the acquisition of Sleep Center of Nevada (SCN) soon, which sees approximately 3,000 sleep patients monthly, with a significant percentage testing positive for obstructive sleep apnea (OSA) [9][12] - The acquisition is anticipated to be accretive to revenue and gross profit shortly after closing [9] Company Strategy and Development Direction - The company is pivoting to create strategic alliances or acquisitions of sleep medical providers to drive sales of OSA treatment appliances and diversify revenue streams [7][8] - The management believes that the SCN acquisition will be transformational, providing a fast track to increase patient treatment and revenue [10][11] - The company is actively exploring additional acquisition opportunities in the sleep medicine sector, with positive reception from the sleep medicine community [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the new business model and its potential for growth, emphasizing the importance of the SCN acquisition [7][10] - The management team has learned valuable lessons from previous partnerships, which will inform future negotiations and operational strategies [36] Other Important Information - The company has signed a non-binding term sheet for a $7.5 million senior loan to facilitate the SCN acquisition and working capital [9] - Cash used in operations for Q1 2025 was $3.8 million, an increase from $2.5 million in Q1 2024 [24][25] Q&A Session Summary Question: Can you expand on the experience with the Rebus Alliance? - The partnership has progressed slower than expected due to internal issues at Rebus, but the company has proven its thesis that a significant percentage of patients prefer VIVOS treatments over CPAP [28][30] Question: What can be learned from the Rebus experience for future partnerships? - The management has learned to optimize revenue and services in a medical insurance-oriented environment, which will be applied to future partnerships [36] Question: What is the expected impact of the SCN acquisition on the P&L? - The acquisition is expected to add significant revenue and become accretive by Q3 2025, with immediate revenue generation from diagnostic services [44][49] Question: How was the acquisition price of $9 million determined? - The valuation was based on a quality of earnings report and the potential patient volume from SCN, with a fair price offered to the current owners [53][56]